Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin, Docetaxel, and Capecitabine ± Trastuzumab as Neoadjuvant Treatment for Early Breast Cancer
NCT00309556Phase 3Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Feb 2005
- Primary completion
- Nov 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Austrian Breast and Colorectal Cancer Study Group. Started Feb 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00309556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309556.